Biogen
NEWS
What’s New at the J.P. Morgan Life Healthcare Conference?
The company has suggested that it plans to undercut both Biogen and Novartis on price in order to make up for being third-to-market.
Biogen is buying a novel CNS-penetrate inhibitor of casein kinase 1 (CK1) from Pfizer to develop for patients with behavioral and neurological symptoms in various psychiatric and neurologic diseases.
Amunix Pharmaceuticals, based in Mountain View, California, entered a licensing deal with Roche. Under the terms of the deal, Roche will pay Amunix $40 million upfront.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
According to an analysis conducted on Jan. 1, more than 250 drugs manufactured by different companies saw price increases.
Looking back over the past year and even decade, STAT News takes a look back at the best drugs approved over the past 10 years in its weekly Readout podcast.
As Biogen stays in the hunt for an Alzheimer’s treatment with the recent presentation of data about aducanumab made at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference on December 5, it’s expanding its pipeline.
The company indicated it is shutting down its gosuranemab program for PSP and other primary tauopathies.
JOBS
IN THE PRESS